Company intelligence / Profile preview

AnorMED Inc.

Vancouver, British Columbia, Canadaprnewswire.com ↗

Ownership: Private
Development stage: Commercial

Overview

At the time of its acquisition by Genzyme in late 2006, AnorMED’s lead product candidate Mozobil was a late-stage therapy for hematopoietic stem cell transplantation and expected to launch commercially around 2008. The company also had programs targeting HIV and cardiac tissue repair but prioritized its validated hematology/oncology pipeline.

Therapeutic areas: Infectious DiseasesCardiovascularHematology
Modalities: Small molecules (notably chemokine receptor antagonists)
Industry: Biotech

Drug pipeline

1 asset

plerixafor

Commercial

Indications: Non-Hodgkin lymphoma, Multiple myeloma

Partnerships

No major disclosed partnerships prior to Genzyme's acquisition

Beyond the preview

Go deeper on AnorMED Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AnorMED Inc..

Explore the full profile